AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

AdAlta AD-214 Phase I extension study results forecast for release at end of February

Results crucial as AdAlta looks to advance partnering discussions to take asset to Phase II trial

1AD’s trademarked i-body platform advancing next generation of protein therapeutics

Special Report:  The countdown is on to the results of AdAlta’s AD-214 Phase I extension study on track later this month with the clinical stage biotech gearing up for partnering opportunities to advance next phase studies.

The AdAlta (ASX:1AD) Phase I extension study for the use of AD-214 in treatment of Idiopathic Pulmonary Fibrosis (IPF) – a common disease that causes thickening and scarring (fibrosis) of lung tissue – is aimed at reinforcing the safety profile and potential efficacy of the planned Phase II dose.

Countdown on to AdAlta trial results as biotech advances partner discussions - Stockhead Report